This was posted on another site: "This week's Feature profiles Melbourne, Australia-based Agenix (ASX:AGX; NASDAQ:AGXLY) and its ThromboView monoclonal antibody that detects live blood clots anywhere in the body. As CEO Nicholas Weston tells Leonard Zehr, the company is in partnering talks for ThromboView as it readies the product for Phase 3 clinical trials."
http://biotuesdays.com/2012/08/07/agenix-readies-thromboview-for-late-stage-clinical-trials/
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.949M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 35536991 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 7769726 | 9 |
View Market Depth
| Last trade - 16.21pm 01/08/2025 (20 minute delay) ? |
| CT1 (ASX) Chart |
Day chart unavailable